KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

PURPOSE: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti-EGFR targeted therapy (cetuximab or panitumumab). However, it remains uncertain w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ogino, Shuji, Meyerhardt, Jeffrey A., Irahara, Natsumi, Niedzwiecki, Donna, Hollis, Donna, Saltz, Leonard B., Mayer, Robert J., Schaefer, Paul, Whittom, Renaud, Hantel, Alexander, Benson, Al B., Goldberg, Richard M., Bertagnolli, Monica M., Fuchs, Charles S.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2787689/
https://ncbi.nlm.nih.gov/pubmed/19934290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1570
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items